top of page
HER-2 IHC W/ INTERP
Product Details
Lack of HER-2 protein overexpression or gene amplification suggests the patient will not respond to trastuzumab therapy; however, clinical trials are needed to confirm this presumption. Similarly, trastuzumab response, or lack thereof, in patients with confirmed equivocal HER-2 test results is uncertain. Trastuzumab is clinically indicated only for patients in whom HER-2 protein overexpression or gene amplification can be confirmed.
Alternative Name(s)
HercepTest®
Test Prep: None Indicated
bottom of page